Profilin-10 Antibody

What are profilins and PR-10 proteins, and how do they contribute to allergenic cross-reactivity?

Profilins are ubiquitous cytoskeletal proteins (12-15 kDa) found across plant and animal kingdoms with highly conserved structural elements. They function as actin-binding proteins in all eukaryotic cells, regulating cytoskeleton dynamics. In allergology, profilins represent significant pan-allergens responsible for cross-reactivity between diverse plant sources. Their conserved three-dimensional structure includes two α-helices and a five-stranded anti-parallel β-sheet, with recognition by IgE antibodies spanning multiple conserved epitopes .

PR-10 proteins (Pathogenesis-Related proteins group 10), including the well-characterized Bet v 1 homologues, constitute another family of conserved plant proteins implicated in pollen-food allergy syndrome. These 17-18 kDa proteins are found in both pollen and plant-derived foods, demonstrating significant structural homology despite variable sequence identity. The cross-reactivity between PR-10 proteins contributes substantially to clinical manifestations of oral allergy syndrome .

Both protein families enable cross-reactivity through their structural conservation across species, leading to recognition by the same antibodies. The prevalence of Pollen Food Allergy Syndrome (PFAS) resulting from these cross-reactions varies from 9.6% to 55% worldwide according to geographic location, local diet, and regional prevalence of atopic diseases . This variation reflects differences in sensitization patterns to aeroallergens containing these proteins, particularly birch pollen in northern Europe versus grass pollens in other regions.

Methodologically, researchers distinguish these cross-reactivity patterns through recombinant allergen-based component-resolved diagnostics, inhibition ELISA experiments, Western blot analysis using specific monoclonal antibodies, and basophil activation tests with purified allergens. These approaches allow for detailed mapping of sensitization profiles and cross-reactivity patterns in research populations.

How can researchers distinguish between sensitization patterns to profilins versus PR-10 proteins in clinical samples?

Distinguishing between sensitization patterns to profilins and PR-10 proteins requires a multi-faceted methodological approach for accurate characterization in research contexts. Component-resolved diagnostics (CRD) forms the foundation of this differentiation, using purified or recombinant allergen components to detect specific IgE antibodies in patient sera. Researchers typically test for sensitization to specific profilins (e.g., Bet v 2, Phl p 12) and PR-10 proteins (e.g., Bet v 1 homologues) to establish distinct sensitization profiles .

Clinical correlation provides valuable confirmatory data, as sensitization to PR-10-like proteins and profilins without Lipid Transfer Proteins (LTPs) associates primarily with oral allergy syndrome rather than systemic reactions . This clinical pattern helps distinguish these sensitization profiles from more severe phenotypes. Cross-inhibition studies further clarify the primary sensitizing allergen family, with ELISA inhibition assays where patient sera are pre-incubated with purified profilins or PR-10 proteins before testing binding to allergen extracts.

Geographic and seasonal analysis introduces additional differentiation, as PR-10 sensitization predominates in northern Europe (due to birch pollen exposure) while profilin sensitization may be more prevalent in grass pollen-dominant regions . This epidemiological approach complements laboratory findings. For research efficiency, minimal testing panels can include Bet v 1 or Pru p 1 (peach homologue) for PR-10 sensitization, Phl p 12 (grass) or Pru p 4 (peach homologue) for profilin sensitization, and Pru p 3 (peach) for LTP sensitization .

The integration of these methodological approaches enables researchers to categorize subjects into distinct sensitization profiles, which has important implications for understanding cross-reactivity mechanisms, developing targeted therapies, and predicting clinical manifestations in research populations with different aeroallergen exposures and dietary habits.

What experimental techniques are most effective for characterizing profilin-antibody interactions?

Multiple complementary techniques provide comprehensive characterization of profilin-antibody interactions in research settings. Enzyme-Linked Immunosorbent Assay (ELISA) represents the most widely accessible approach, with direct binding ELISA measuring relative affinity and specificity, inhibition ELISA determining cross-reactivity patterns and epitope relationships, and sandwich ELISA enabling detection of native profilins in complex mixtures. ELISA experiments have reliably quantified differential binding of monoclonal antibodies to various profilins, as evidenced by the varying recognition patterns of mAbs 2D10 and 1B4 for profilins from different plant sources .

Surface Plasmon Resonance (SPR) provides critical kinetic data, including real-time binding kinetics (kon and koff rates), affinity constant (KD) determination, epitope mapping through competitive binding experiments, and temperature-dependent binding analysis. This technique offers particular value for understanding the thermodynamics and kinetics of antibody-profilin interactions. Bio-Layer Interferometry (BLI) offers similar advantages with higher throughput potential, enabling label-free detection of binding interactions, screening of multiple antibodies, and stability testing under various buffer conditions.

For structural characterization, X-ray crystallography provides atomic-level resolution of antibody-profilin complexes, identification of specific interaction residues, and insights into the structural basis for cross-reactivity. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) offers complementary structural information about binding interfaces without requiring crystallization.

Functional assessment methods include basophil activation tests, which provide functional evaluation of antibody blocking capacity, serving as an in vitro model of allergic response, and enabling comparison of different antibody clones for inhibitory potential. Research data shows that monoclonal antibodies like 2D10 can inhibit the interaction of IgE and IgG4 antibodies from sera of latex- and maize-allergic patients by 90% and 40%, respectively, demonstrating the power of these techniques for characterizing therapeutic potential .

What structural features of profilins determine antibody recognition and cross-reactivity patterns?

The structural determinants of antibody recognition and cross-reactivity in profilins involve several key molecular features that influence binding specificity and affinity. Alpha-helical regions, particularly α-helices 1 and 3 at the amino and carboxy-terminal regions, form critical epitopes for antibody recognition. Research has demonstrated that the 2D10 monoclonal antibody epitope comprises these α-helices, while the 1B4 antibody recognizes the opposite side of the profilin surface . These structural elements show high conservation across plant profilins, contributing significantly to cross-reactivity patterns observed in clinical and research settings.

Surface charge distribution plays a crucial role in antibody binding, with the distribution of negative charges on profilins' surfaces at α-helices 1 and 3 significantly influencing recognition patterns. Research has established that this charge distribution determines monoclonal antibody binding and explains profilin IgE cross-reactivity patterns . This electrostatic component of recognition provides important insights for designing antibodies with specific binding properties or predicting cross-reactivity based on sequence analysis.

Specific amino acid residues serve as critical determinants of recognition, with residue D130 at α-helix 3 identified as essential for recognition by specific antibodies. Mutation studies have demonstrated that substitution at this position significantly alters antibody binding affinity and specificity. Structural analysis suggests that profilins containing glutamic acid at position 130 (E130) show reduced binding with certain antibodies compared to those with aspartic acid (D130) . This single residue difference helps explain why profilins like rPhl p 12.0101, rFra e 2.2, and rZea m 12.0105 demonstrate less binding with specific antibodies.

Most antibodies recognize conformational rather than linear epitopes on profilins, with these epitopes typically spanning multiple secondary structure elements. This conformational dependency means that native protein folding is essential for antibody recognition, with denatured profilins often showing reduced antibody binding. These structural insights provide valuable guidance for epitope-focused vaccine design and therapeutic antibody development.

How can epitope mapping approaches be optimized for profilin antibodies?

Optimizing epitope mapping for profilin antibodies requires a multi-method approach to overcome challenges related to conformational epitopes that dominate these interactions. Computational prediction coupled with experimental validation provides a robust starting point, beginning with in silico algorithms to predict potential epitopes based on surface accessibility calculations, hydrophilicity profiles, and sequence conservation analysis across homologous profilins. These predictions require subsequent experimental validation using complementary techniques to confirm and refine epitope boundaries.

Site-directed mutagenesis represents a powerful strategy for experimental epitope mapping, incorporating systematic alanine scanning of surface-exposed residues, creation of chimeric proteins with swapped regions between cross-reactive profilins, expression of truncated variants to identify essential binding regions, and point mutations at charged residues. Research has identified position D130 as particularly critical for antibody recognition, with mutations at this position significantly altering binding profiles . This methodology provides direct functional evidence for epitope composition.

Hydrogen-deuterium exchange mass spectrometry (HDX-MS) offers advantages for conformational epitope mapping, measuring solvent accessibility changes upon antibody binding and identifying protected regions likely involved in the epitope. This technique works with native protein without requiring mutations and can detect subtle conformational changes induced by binding. Protocol optimization should include shorter exchange times (10s-1min) to capture fast-exchanging regions relevant to surface epitopes.

Structural biology approaches provide the highest resolution data, with X-ray crystallography or cryo-EM of antibody-profilin complexes delivering atomic-level resolution of binding interfaces and revealing precise molecular interactions. While these techniques present challenges in obtaining crystals of sufficient quality, researchers can optimize results using Fab or Fv fragments instead of complete antibodies to improve crystallization properties.

Research combining computational modeling with experimental validation has proven most effective for comprehensive epitope mapping. Molecular modeling of Fv regions of monoclonal antibodies 1B4 and 2D10 against latex profilin (rHev b 8), followed by docking simulations of the Fvs-rHev b 8 complexes, successfully identified that the 2D10 epitope comprises α-helices 1 and 3, while 1B4 recognized the opposite side of the profilin surface . This integrated approach provides the most complete understanding of epitope architecture.

What methodological approaches best identify critical residues for antibody cross-reactivity in profilins?

Identifying critical residues that determine antibody cross-reactivity in profilins requires strategic experimental design combining multiple complementary approaches. Cross-species binding analysis forms the foundation, with systematic ELISA testing of antibody binding to profilins from diverse species, quantitative comparison of binding affinities (IC50 values), and correlation analysis between binding strength and sequence/structural differences. Research has demonstrated the effectiveness of this approach, with mAb 2D10 showing differential recognition of profilins: strong binding to Art v 4 and Amb a 8 (88%), moderate binding to Bet v 2 (54%) and Fra e 2 (42%), and minimal binding to Zea m 12 (11%) . These binding patterns reveal evolutionary conservation of epitopes.

Targeted mutagenesis approaches provide direct experimental evidence for critical residues, incorporating single point mutations at non-conserved residues between strongly and weakly binding profilins, creation of residue swap mutants (e.g., D130E in profilins), charge reversal mutations to test electrostatic contributions, and multiple mutation constructs to test synergistic effects. Research has demonstrated that residue D130 at α-helix 3 is essential for 2D10 recognition, with profilins containing E130 showing reduced binding . This systematic mutagenesis strategy enables precise mapping of contribution from individual amino acids.

Structural bioinformatics integration enhances interpretation of experimental findings, utilizing homology modeling of profilins with unknown structures, surface electrostatic potential mapping, molecular dynamics simulations to identify flexible regions, and in silico alanine scanning to predict energetic contributions. Research has established correlation between surface charge distribution at α-helices 1 and 3 and antibody recognition patterns , providing mechanistic understanding of binding determinants.

Competitive binding assays offer functional confirmation of critical residues, including inhibition ELISA with various profilins as competing antigens, surface plasmon resonance competition experiments, and epitope binning to classify antibodies by their binding regions. Protocol optimization should include pre-incubation of antibody with competitor before adding to immobilized antigen to ensure equilibrium conditions during measurement.

Functional validation completes the analysis framework, incorporating basophil activation tests using recombinant profilin variants, IgE competition assays with sera from allergic patients, and in vitro mast cell degranulation assays. Research has shown that when sensitized rat basophilic leukemia cells with IgE antibody formed a complex with rHev b 8-2D10, degranulation was prevented, confirming the biological relevance of the identified epitope .

How can mutagenesis studies be designed to evaluate antibody recognition determinants in profilins?

Designing effective mutagenesis studies to evaluate antibody recognition determinants in profilins requires strategic planning across multiple experimental dimensions. Strategic mutation site selection forms the foundation, beginning with sequence alignment analysis of strongly versus weakly recognized profilins to identify candidate residues. Research should focus on surface-exposed residues, particularly in α-helices 1 and 3, which have been identified as critical epitope regions . Priority should be given to charged residues (D, E, K, R) as these often contribute significantly to antibody binding through electrostatic interactions. Residue D130 merits particular attention, as research has established its critical role in antibody recognition .

Mutation design strategy requires careful consideration of physicochemical properties, incorporating conservative mutations (D→E, K→R) to test subtle effects while also including non-conservative mutations to drastically alter charge or hydrophobicity. Alanine scanning provides unbiased assessment of residue contribution by removing side chain interactions without introducing new properties. Reciprocal mutations between profilins with different binding properties offer particular insight into determinants of specificity. For complex epitopes, creation of chimeric constructs swapping entire secondary structure elements between profilins can identify regions rather than individual residues.

Expression system optimization ensures high-quality protein production, utilizing E. coli BL21(DE3) with codon optimization, IPTG concentration and induction temperature calibration, and incorporation of solubility-enhancing tags when necessary. Parallel production of wild-type and mutant proteins under identical conditions minimizes experimental variables, while rigorous quality control through circular dichroism and thermal stability analysis ensures comparable folding and stability between variants.

Comprehensive binding analysis protocols should incorporate multiple complementary techniques, including direct ELISA with immobilized profilins, solution-phase binding studies using BLI or SPR, thermal stability comparison using differential scanning fluorimetry, and circular dichroism to confirm unaltered secondary structure. Standardized protocols enable quantitative comparison of binding properties across mutant variants.

Structural biology approaches provide validation at atomic resolution, with crystallography of selected mutants with bound antibody, hydrogen-deuterium exchange mass spectrometry to map interaction surfaces, and NMR epitope mapping for solution-state validation. In silico molecular dynamics simulations complement experimental data by modeling effects of mutations on protein dynamics and interaction energetics.

What experimental designs best assess the clinical relevance of anti-profilin antibodies in allergic patients?

Assessing the clinical relevance of anti-profilin antibodies requires experimental designs that bridge laboratory findings with patient outcomes through multiple complementary approaches. Comprehensive patient stratification establishes the foundation, incorporating detailed clinical history focused on pollen-food syndrome manifestations, skin prick testing with native and recombinant allergens, component-resolved diagnostics using purified allergens, and tracking of seasonal variation in symptoms and antibody levels. This stratification enables correlation of antibody profiles with clinical phenotypes, with research showing PFAS prevalence varies from 9.6% to 55% worldwide based on geographic location, local diet, and atopic disease prevalence .

Ex vivo functional assays provide critical mechanistic insights, incorporating basophil activation tests using patient blood and purified profilins, inhibition studies with anti-profilin monoclonal antibodies, IgE-facilitated allergen binding (FAB) assays, and T-cell proliferation and cytokine production in response to profilins. Protocol optimization should include recombinant profilins at physiologically relevant concentrations and appropriate positive and negative controls for each assay system.

Cross-reactivity profiling characterizes the molecular basis of clinical manifestations, utilizing IgE inhibition assays with panels of recombinant profilins, epitope mapping of patient IgE versus monoclonal antibodies, competition studies between IgE and IgG4 antibodies, and quantification of specific IgG/IgA responses alongside IgE. Data interpretation should correlate molecular findings with symptom severity across different allergen sources to establish clinical significance.

Longitudinal monitoring designs capture the dynamic nature of allergic responses, tracking seasonal changes in antibody levels and specificity, effects of allergen avoidance on antibody profiles, changes following allergen-specific immunotherapy, and correlation with symptom severity using validated clinical scores. Statistical approaches should employ mixed-effects models accounting for repeated measures to properly analyze longitudinal datasets.

Provocation testing protocols, while ethically challenging, provide the most direct evidence of clinical relevance. These may include double-blind placebo-controlled food challenges, nasal/conjunctival allergen provocation tests, monitored natural exposure studies, and assessment of basophil reactivity before and after challenges. Ethical considerations necessitate careful risk assessment and emergency protocols. Research has demonstrated that sensitization to PR-10-like proteins and profilins without LTP primarily associates with oral allergy syndrome rather than systemic reactions , demonstrating how these experimental approaches distinguish clinically relevant sensitization patterns.

How can researchers distinguish the roles of α4β1 integrin and TLR4 in profilin-related responses?

Understanding the cooperative roles of α4β1 integrin and TLR4 in profilin-related responses requires sophisticated experimental designs that selectively target each pathway. Receptor-specific blocking experiments form the foundation of this approach, utilizing blocking antibodies against either TLR4 or the α4 subunit of integrin to assess their individual contributions. Research has demonstrated that up-regulation of inflammatory mediators like TNF-α and VCAM1 in response to extracellular matrix components is significantly inhibited by blocking antibodies to either TLR4 or α4, suggesting cooperative signaling between these receptors .

RNA interference techniques provide complementary verification, with siRNA knockdown of α4 integrin subunit enabling assessment of TLR4-dependent versus integrin-dependent gene expression. Experiments have shown that α4 knockdown significantly reduces the expression of several fibrotic genes, confirming the integrin's role in signaling cascades . This genetic approach complements pharmacological inhibition studies and allows detailed pathway dissection.

Pharmacological inhibition studies further delineate receptor contributions, incorporating TLR4 inhibitors (e.g., TAK-242), NF-κB inhibitors (e.g., Bay 11-0872), and integrin signaling inhibitors to assess downstream pathway convergence. Research has demonstrated that inhibition of either receptor pathway significantly reduces inflammatory gene expression, with combination treatments showing additive or synergistic effects , suggesting pathway convergence at key signaling nodes.

Mechanistic pathway analysis determines points of signaling integration, incorporating phosphorylation studies of key signaling intermediates, subcellular localization of transcription factors like NF-κB, chromatin immunoprecipitation to assess promoter binding, and transcriptional reporter assays to measure pathway activation. These mechanistic studies reveal that both α4β1 integrin and TLR4 regulate NF-κB-dependent induction of fibroinflammatory gene expression .

Functional outcome measurements complete the experimental framework, utilizing cellular assays such as migration, adhesion, cytokine production, and matrix deposition to assess biological consequences of receptor activation. Research has shown that cells adherent to specific matrix components show enhanced cytokine production in response to TLR4 ligands, with this enhanced response being α4β1-dependent . This integrative approach reveals the complex interplay between adhesion receptors and pattern recognition pathways in regulating immune responses.

How can the inhibitory potential of anti-profilin antibodies be quantified for therapeutic applications?

Quantifying the inhibitory potential of anti-profilin antibodies for therapeutic applications requires robust methodological approaches that assess multiple aspects of efficacy and specificity. In vitro inhibition assays provide the foundation for evaluation, incorporating IgE-blocking ELISA to measure inhibition of patient IgE binding to profilins, competitive ELISA formats with varying antibody concentrations, calculation of IC50 values for quantitative comparison, and determination of inhibition curves across patient populations. Research has demonstrated the effectiveness of this approach, with monoclonal antibodies 1B4 and 2D10 against latex profilin (rHev b 8) inhibiting the interaction of IgE and IgG4 antibodies from sera of latex- and maize-allergic patients by 90% and 40%, respectively .

Cell-based functional inhibition measurements validate the biological relevance of binding inhibition, utilizing basophil activation tests with patient blood, RBL (rat basophilic leukemia) cell degranulation assays, measurement of mediator release (histamine, β-hexosaminidase), and dose-response relationships with varying antibody concentrations. Research has confirmed that when sensitized RBL cells with IgE antibody formed a complex with rHev b 8-2D10, degranulation was prevented, demonstrating functional blocking activity .

Epitope-specific inhibition analysis characterizes mechanism of action, incorporating competition studies with panels of well-characterized epitope-specific antibodies, epitope binning to classify therapeutic antibody candidates, correlation between epitope specificity and inhibitory potential, and structural mapping of inhibitory epitopes. Research has established that the mAb 2D10 epitope comprises α-helices 1 and 3 at the amino and carboxy-terminal regions, similar to regions recognized by allergic patients' IgE , explaining its effective inhibitory capacity.

Cross-reactivity inhibition profiling determines therapeutic breadth, testing inhibitory capacity across multiple profilins, correlating sequence/structural similarity with inhibition efficacy, developing broadly inhibitory versus specific antibodies, and optimizing antibody cocktails for broader coverage. Data shows differential recognition patterns, with mAb 2D10 strongly recognizing Art v 4 and Amb a 8 (88%), and showing varying levels of recognition for other profilins , which guides selection of candidates for broad applicability.

Stability and pharmacokinetic considerations complete the evaluation framework, incorporating thermal stability testing under physiological conditions, pH resistance profiling for mucosal applications, half-life determination in relevant biological fluids, optimization of antibody format (whole IgG, Fab, single-chain), and production scalability assessment. These parameters ensure that promising inhibitory antibodies also possess the physical properties necessary for therapeutic development.